Abstract:Key PointsCell-free DNA (cfDNA) is released predominantly by cell death into the bloodstream, although active secretion may have a role. Since the discovery of fetal cfDNA in the maternal circulation, cfDNA analysis has been rapidly implemented in clinical practice for noninvasive prenatal testing.Mutations were first detected in cfDNA more than two decades ago, and interest in circulating tumour DNA (ctDNA) as a noninvasive cancer diagnostic has increased considerably with the development of molecular methods that permit the sensitive detection and monitoring of multiple classes of mutation.ctDNA may have utility at almost every stage of the management of patients with cancer, including diagnosis, minimally invasive molecular profiling, treatment monitoring, the detection of residual disease and the identification of resistance mutations. ctDNA analysis may be broadly considered as a tool both for quantitative analysis of disease burden and for genomic analysis.The identification of ctDNA in individuals before a cancer diagnosis, and in presymptomatic individuals, suggests the possibility of ctDNA analysis as a tool for earlier detection and screening. Noninvasive cancer classification or subtyping has also emerged as a possibility, although for early detection, both technical and biological factors introduce challenges to the detection of mutant DNA in plasma and its interpretation.Monitoring multiple mutations in parallel can enhance the sensitivity of ctDNA detection, can be used to assess the clonal evolution of patients' disease and may identify resistance mutations before clinical progression is observed.ctDNA analysis is beginning to transition from the research setting into the clinic. The US Food and Drug Administration and the European Medicines Agency have approved ctDNA tests for specific indications in the absence of evaluable tumour tissue. Analysis of gene panels in plasma has now become available as a potential clinical tool. Large studies are under way to establish the overall performance and clinical utility of such assays when a tumour biopsy is not available for analysis.Potential applications of ctDNA have been demonstrated by a number of proof-of-principle studies. Prospective clinical trials are beginning to assess the clinical utility of ctDNA analysis for molecular profiling and disease monitoring. The increasing acceptance of ctDNA is enabling the field to move from exploratory ctDNA studies towards clinical trials in which ctDNA guides decision-making.In order to fully exploit the potential utility of liquid biopsies, it is essential that the biology of cfDNA and ctDNA is explored further. The mechanisms of release and degradation, and the factors that affect the representation of ctDNA in plasma, are poorly understood. The nature of ctDNA will be clarified through both large, well-annotated clinical studies and in vivo studies in which variables can be controlled.

Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA

Liquid Biopsies: DNA Methylation Analyses in Circulating Cell-Free DNA

Deoxyribonucleic Acid 5-Hydroxymethylation in Cell-Free Deoxyribonucleic Acid, a Novel Cancer Biomarker in the Era of Precision Medicine

Liquid biopsies based on DNA methylation as biomarkers for the detection and prognosis of lung cancer

Current Challenges of Methylation-Based Liquid Biopsies in Cancer Diagnostics

DNA methylation signatures in circulating cell-free DNA as biomarkers for the early detection of cancer

New Path of Cancer Liquid Biopsy : DNA Methylation Detection by Digital PCR

DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.

Circulating tumor DNA methylation: a promising clinical tool for cancer diagnosis and management

Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy

Challenges and Prospects of Cell-Free DNA in Precision Oncology

Plasma Cell-Free Tumor Methylome as a Biomarker in Solid Tumors: Biology and Applications

"Liquid biopsy"-ctDNA detection with great potential and challenges.

Cell‐free DNA‐associated Multi‐feature Applications in Cancer Diagnosis and Treatment

Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer

Liquid biopsy: unlocking the potentials of cell-free DNA

Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization

Dissecting the nuances of cancer epigenomics in liquid biopsy

Unveiling targeted cell-free DNA methylation regions through paired methylome analysis of tumor and normal tissues

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification